Article information
Abstract
Corticosteroids are the principal cause of secondary osteoporosis due to drug treatment. Doses of more than 5 mg daily and periods of treatment lasting more than 3 months increase the risk of osteoporosis and fragility fractures. It is therefore essential to be aware of measures to reduce the risk of osteoporosis in our patients.
Key words:
corticosteroids
osteoporosis
bisphosphonates
Resumen
La primera causa de osteoporosis secundaria a fármacos son los glucocorticoides. Dosis diarias superiores a 5 mg o dosificación durante más de 3 meses incrementan la osteoporosis y las fracturas por fragilidad. Resulta crucial conocer las medidas para minimizar la osteoporosis en nuestros enfermos.
Palabras clave:
corticosteroides
osteoporosis
bifosfonatos
Full text is only aviable in PDF
References
[1.]
M.B. Sulzberger, V.H. Witten.
Effect of topically applied compound F in selected dermatoses.
J Invest Dermatol, 19 (1952), pp. 101-102
[2.]
B. Brazzini, N. Pimpinelli.
New and established topical corticosteroids in Dermatology. Clinical pharmacology and therapeutic use.
Am J Clin Dermatol, 3 (2002), pp. 47-58
[3.]
A. Markham, H.M. Bryson.
Deflazacort. A review of its pharmacological properties and therapeutic efficacy.
Drugs, 50 (1995), pp. 317-333
[4.]
C. Gennari.
Differential effect of glucocorticoids on calcium absorption and bone mass.
Br J Rheumatol, 32 (1993), pp. S11-S14
[5.]
D.B. Robertson, H.I. Maibach.
Adverse systemic effects of TCS.
TCS, pp. 163-169
[6.]
L.G. Raisz.
Pathogenesis of osteoporosis: concepts, conflicts and prospects.
J Clin Invest, 115 (2005), pp. 3318-3325
[7.]
NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy.
Osteoporosis prevention, diagnosis, and therapy.
JAMA, 285 (2001), pp. 785-795
[8.]
A.M. Parfitt, A.R. Villanueva, J. Foldes, D.S. Rao.
Relations between histologic indexes of bone formation: implications for the pathogenesis of spinal osteoporosis.
J Bone Miner Res, 10 (1995), pp. 466-473
[9.]
EPOS Group.
Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS).
J Bone Miner Res, 17 (2002), pp. 716-724
[10.]
M.R. MacAdams, R.H. White, B.E. Chipps.
Reduction of serum testosterone levels during chronic glucocorticoid therapy.
Ann Intern Med, 104 (1986), pp. 648-651
[11.]
Y.S. Chyun, B.E. Kream, L.G. Raisz.
Cortisol decreases bone formation by inhibiting periosteal cell proliferation.
Endocrinology, 114 (1984), pp. 477-480
[12.]
P.N. Sambrook, J.A. Eisman, G.D. Champion, N.A. Pocock.
Sex hormone status and osteoporosis in postmenopausal women with rheumatoid arthritis.
Arthritis Rheum, 31 (1988), pp. 973-978
[13.]
R.G. Klein, S.B. Arnaud, J.C. Gallagher, H.F. Deluca, B.L. Riggs.
Intestinal calcium absorption in exogenous hypercortisolism. Role of 25-hydroxyvitamin D and corticosteroid dose.
J Clin Invest, 60 (1977), pp. 253-259
[14.]
B.P. Lukert, L.G. Raixz.
Glucocorticoid-induced osteoporosis: Pathogenesis and management.
Ann Intern Med, 112 (1990), pp. 352-364
[15.]
R.F. Laan, P.L. van Riel, L.B. van de Putte, L.J. van Erning, M.A. van’t Hof, J.A. Lemmens.
Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study.
Ann Intern Med, 119 (1993), pp. 963-968
[16.]
C. Cooper, C. Coupland, M. Mitchell.
Rheumatoid arthritis, corticosteroid therapy and hip fracture.
Ann Rheum Dis, 54 (1995), pp. 49-52
[17.]
G.M. Hall, T.D. Spector, P.D. Delmas.
Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy.
Arthritis Rheum, 38 (1995), pp. 902-906
[18.]
N.A. Morrison, J.C. Qi, A. Tokita, P.J. Kelly, L. Crofts, T.V. Nguyen, et al.
Prediction of bone density from vitamin D receptor alleles.
Nature, 367 (1994), pp. 284-287
[19.]
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis.
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update.
Arthritis Rheum, 44 (2001), pp. 1496-1503
[20.]
B.T. Summey, G. Yosipovitch.
Glucocorticoid-induced bone loss in dermatologic patients.
Arch Dermatol, 142 (2006), pp. 82-90
Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
